HER-2 I655V
|
Breast Cancer
|
HER-2 I655V
|
Breast Cancer
|
trastuzumab Sensitive: C3 – Early Trials
|
trastuzumab Sensitive: C3 – Early Trials
|
HER-2 I655V
|
NSCLC
|
HER-2 I655V
|
NSCLC
|
pyrotinib Sensitive: C3 – Early Trials
|
pyrotinib Sensitive: C3 – Early Trials
|
HER-2 I655V
|
HER2 Positive Breast Cancer
|
HER-2 I655V
|
HER2 Positive Breast Cancer
|
neratinib Sensitive: D – Preclinical
|
neratinib Sensitive: D – Preclinical
|